Key Takeaways:
Metis TechBio Co. (07666.HK) granted Deerfield-backed Boulevard Bio exclusive global rights to develop and commercialize its trispecific T cell engager MTS-128, securing a $20 million upfront payment and eligibility for as much as $1.6 billion in milestone payments plus tiered royalties.
"Trispecific TCEs represent a meaningful advance over bispecifics because they can engage three biological targets simultaneously, potentially improving tumor cell killing while reducing off-target toxicity," said Dr. Hongming Chen, co-founder of Metis TechBio and a member of the U.S. National Academy of Engineering. "This partnership validates our NanoForge platform's ability to design complex protein therapeutics."
MTS-128 was designed using Metis TechBio's NanoForge platform, an AI-driven system that combines protein design with a proprietary lipid nanoparticle library exceeding 10 million lipids. Trispecific T cell engagers differ from traditional bispecific TCEs by modulating three mechanisms at once, which the company says can improve the therapeutic window and cell-killing efficiency. The asset is in pre-clinical development, with Boulevard Bio assuming responsibility for future clinical trials, manufacturing and commercialization.
The deal provides a critical validation point for Metis TechBio, which listed in Hong Kong in 2020 as the world's first publicly traded AI drug delivery company. The company has built four core AI solutions covering nano-delivery system design, mRNA sequence design, protein design and small-molecule formulation. Its current market capitalization stands at about HK$15.4 billion, with an average daily trading volume of 7.2 million shares. The stock fell 0.8% in the session following the announcement.
For Deerfield, a healthcare-focused investment firm with a track record in biotech, the partnership signals confidence in AI-enabled immunotherapy design. The $1.6 billion milestone structure ties most of the deal's value to successful development and commercialization, a common structure in early-stage biotech licensing that limits downside for the licensee while offering the licensor substantial upside if the asset reaches the market. Metis TechBio did not disclose a timeline for MTS-128's first clinical trial.
This article is for informational purposes only and does not constitute investment advice.
